Sanofi's "star small molecule" protein degradation agent new drug has been approved for clinical trials in China.

On January 20, the latest announcement on the official website of the China National Medical Products Administration Drug Evaluation Center (CDE) revealed that the Class 1 new drug SAR444656, applied by Sanofi (SNY.US), has obtained clinical trial implicit approval. The intended indications for development include atopic dermatitis (AD) and hidradenitis suppurativa (HS). The screenshot is from the CDE official website. Public information shows that KT-474 (SAR444656) is an IRAK4 protein degrader developed jointly by Kymera Therapeutics and Sanofi. This product was previously listed as one of the top 10 "star" small molecules for the year 2023 on the website drughunter.com. In addition, Sanofi introduced its lineup of new drugs with significant potential at the 2023 R&D Day, including SAR444656. According to the ClinicalTrials website, Sanofi is conducting two international multicenter phase 2 clinical studies to evaluate the efficacy and safety of SAR444656 in treating moderate to severe hidradenitis suppurativa in adults and moderate to severe atopic dermatitis in adults. The approval of SAR444656 for clinical trials in China means that this product will also enter the clinical research stage in China.